Plain-English translation of NCT06612840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called , which is a type of antibody designed to fight cancer. Researchers want to find out if is safe, how your body processes it, and whether it can help shrink tumors in people with advanced lung cancer or other solid cancers. You would receive the medication as an intravenous infusion (through an IV) over a 3-week cycle, and may continue treatment if it's helping you.
Current treatments for advanced lung cancer and solid tumors don't work well enough for all patients. This trial exists to see if this new antibody treatment could offer hope to people whose cancers have not responded to standard therapies or have spread.
You likely qualify if…
You likely don't qualify if…
You would visit the study site to receive the medication as an intravenous infusion during a 3-week treatment cycle. If the treatment is helping you and you tolerate it well, you can continue receiving additional cycles. Researchers will monitor you closely with blood tests, scans, and check-ups to watch for side effects and to see if your tumors are shrinking. The study will continue until your cancer progresses, you experience unacceptable side effects, or your doctor decides to stop treatment for another reason.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China